Pharmacotherapy for Children and Adolescents with Conduct Problems

  • Helen L. Smith
  • David R. Coghill
Chapter

Abstract

Conduct problems can be formally classified as “disruptive behavior disorders” which include conduct disorder (CD), oppositional defiant dis­order (ODD), and disruptive behavior disorder not otherwise specified (DBD-NOS) in the Diagnostic and Statistical Manual 4th edition (DSM-IV-TR; American Psychiatric Association, 2000). Conduct Disorder is a serious disorder which is characterized by persistent antisocial behavior and can be helpfully divided into early (before the age of 10 years) or late onset. Clinicians are often pessimistic about the effectiveness of treatment options available to manage CD and ODD; in particular, many are skeptical about the value of pharmacological treatments for managing CD and ODD, but is this skepticism justified?

Keywords

Attention Deficit Hyperactivity Disorder Conduct Problem Conduct Disorder Stimulant Medication Conduct Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Achenbach, T. M. (1991). Manual for the child behavior checklist/4–18 and 1991 profile. Burlington: University of Vermont, Department of Psychiatry.Google Scholar
  2. Allison, D. B., Mentore, J. L., Heo, M., et al. (1999). Antipsychotic induced weight gain a comprehensive research synthesis. American Journal of Psychiatry, 156, 416–432.Google Scholar
  3. Aman, M., De Smedt, G., Lyons, B., Findling, R., & Risperidone Disruptive Behavior Study Group. (2002). Double –blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. American Journal of Psychiatry, 159, 1337–1346.CrossRefGoogle Scholar
  4. Aman, M. G., Singh, N., Stewart, A. W., & Field, C. J. (1985). Psychometric characteristics of the Abberrant Behavior Checklist. American Journal of Mental Deficiency, 89, 492–502.PubMedGoogle Scholar
  5. Aman, M. G., Tasse, M., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Research in Developmental Disability, 17, 41–57.CrossRefGoogle Scholar
  6. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text revision). Washington, DC: American Psychiatric Association.CrossRefGoogle Scholar
  7. Armenteros, J. L., & Lewis, J. E. (2002). Citalopram treatment for impulsive aggression in children and adolescents: an open pilot study. Journal of American Academy of Child and Adolescent Psychiatry, 41(5), 522–529.CrossRefGoogle Scholar
  8. Banaschewski, T., Coghill, D., Santosh, P., et al. (2006). Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. European Journal of Child and Adolescent Psychiatry, 15(8), 476–495.CrossRefGoogle Scholar
  9. Bangs, M., Hazell, P., Danckaerts, M., Hoare, P., Coghill, D., Wehmeier, P., et al. (2006). Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics, 121, e314–e320.PubMedCrossRefGoogle Scholar
  10. Barker, P., & Fraser, I. (1968). A controlled trial of haloperidol, in children. British Journal of Psychiatry, 114, 855–857.PubMedCrossRefGoogle Scholar
  11. Caldwell, M., Maltereer, M., Umstead, D., & McCormick, D. (2008). A retrospective evaluation of adjunctive risperidone treatment in severely behaviourally disordered boys receiving psychosocial treatment. Journal of Child and Adolescent Psychopharmacology, 18(1), 34–43.PubMedCrossRefGoogle Scholar
  12. Campbell, M., Adams, P., Small, A., Kafantaris, V., Silva, R., Shell, S., et al. (1995). Lithium in hospitalized aggressive children with conduct disorder: a double blind and placebo controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 34(4), 445–453.PubMedCrossRefGoogle Scholar
  13. Campbell, M., Small, A., Green, W., Jennops, S., Perry, R., Bennett, W., et al. (1984). Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalised aggressive children with conduct disorder. Archives of General Psychiatry, 41, 650–656.PubMedCrossRefGoogle Scholar
  14. Campbell, M., Silva, R., Kafantaris, V., Locasio, J., Gonzalez, N., Lee, D., et al. (1991). Predictors of side-effects associated with Lithium administration in children. Psychopharmacology Bulletin, 27(3), 373–380.PubMedGoogle Scholar
  15. Cipriani, A., Barbui, C., & Geddes, J. (2005). Suicide, depression and antidepressants. British Medical Journal, 330, 373–374.PubMedCrossRefGoogle Scholar
  16. Conners, C. (1998). Manual for Conners’ Rating Scale. Toronto: Multi- health care systems.Google Scholar
  17. Connor, D., Glatt, S., Lopez, I., Jackson, D., & Melloni, R. (2002). Psychopharmacology and aggression I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviours in ADHD. Journal of American Academy of Child and Adolescent Psychiatry, 41(3), 253–261.CrossRefGoogle Scholar
  18. Croonenberghs, J., Fegert, J.M., Findling, R., De Smedt, G., Van Dongen, R., & Risperidone disruptive behaviour study group. (2005). Risperidone in children with disruptive behaviour disorders and subaverage intelligence: a 1 year open label study of 504 patients. Journal of American Academy of Child and Adolescent Psychiatry, 44, 67–72.Google Scholar
  19. Cueva, J., Overall, J., Small, A., Armenteros, J., Perry, R., & Campbell, M. (1996). Carbamazepine in aggressive children with Conduct Disorder: a double blind and placebo controlled study. Journal of American Academy of Child and Adolescent Psychiatry, 35(4), 480–490.CrossRefGoogle Scholar
  20. Cunningham, M. A., Pillai, V., & Blachford-Rogers, W. J. (1968). Haloperidol in the treatment of children with severe behaviour disorders. British Journal of Psychiatry, 144, 845–854.CrossRefGoogle Scholar
  21. Curtiss, G., Rosenthal, R., Marohn, R., Ostrar, E., Offer, D., & Trujillo, J. (1983). Measuring delinquent behaviour in inpatient treatment settings: revision and validation of the adolescent antisocial behavior checklist. Journal of American Academy of Child Psychiatry, 22, 459–466.CrossRefGoogle Scholar
  22. Deltito, J. A., Leviton, J., Damone, J., Hajal, F., & Zamberiedetti, M. (1998). Naturalistic experience with the use of divalproex sodium on an inpatient unit for psychiatric patients. Acta Psychiatrica Scandinavica, 97(3), 236–240.PubMedCrossRefGoogle Scholar
  23. Derogatis, L. R., Lipman, R. S., & Covi, L. (1973). SCL-90: an outpatient psychiatric rating scale- preliminary report. Psychopharmacology Bulletin, 9, 13–28.PubMedGoogle Scholar
  24. Donovan, S., Stewart, J., Nunes, E., Quitkin, F., Porides, M., Daniel, W., et al. (2000). Divalproex Treatment for youth with explosive temper and mood lability: a double blind, placebo controlled crossover design. American Journal of Psychiatry, 157, 812–820.CrossRefGoogle Scholar
  25. Donovan, S., Susser, E., Nunes, E., Stewart, J., Quitkin, F., & Klein, D. (1997). Divalproex treatment of disruptive adolescents: a report of 10 cases. Journal of Clinical Psychiatry, 58, 12–15.PubMedCrossRefGoogle Scholar
  26. Findling, R. (2008). Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. Journal of Clinical Psychiatry, 69(suppl 4), 9–14.PubMedGoogle Scholar
  27. Findling, R., McNamara, N., Branicky, L., Schluchter, M., Lemon, E., & Blumer, J. (2000). A double–blind pilot study of risperidone in the treatment of conduct disorder. Journal of American Academy of Child and Adolescent Psychiatry, 39(4), 509–516.CrossRefGoogle Scholar
  28. Findling, R., Reed, M., O’Riordan, M., Demeter, C., Stansbrey, R., & McNamara, N. (2006). Effectiveness, sifter and pharmacokinetics of quetiapine in aggressive children with conduct disorder. Journal of American Academy of Child and Adolescent Psychiatry, 45(7), 792–800.CrossRefGoogle Scholar
  29. Greene, R., & Ablon, S. (2003). Treating explosive kids: the collaborative problem-solving approach. New York: The Guildford Press.Google Scholar
  30. Greenhill, L., Soloman, M., Pleak, R., & Ambrosini, P. (1985). Molindone hydrochloride treatment of hospitalised children with conduct disorder. Journal of Clinical Psychiatry, 46(8), 20–25.PubMedGoogle Scholar
  31. Guy, W. (1976). ECDEU. Assessment for Psychopharmacology. Rockville: National Institute of Mental Health.Google Scholar
  32. Handen, D., & Hardan, A. (2006). Open-label prospective trial of olanzapine in adolescents with sub average intelligence and disruptive behavior disorders. Journal of American Academy of Child and Adolescent Psychiatry, 45(8), 928–935.CrossRefGoogle Scholar
  33. Hazell, P., & Stuart, J. (2003). A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of American Academy of Child and Adolescent Psychiatry, 42(8), 886–894.CrossRefGoogle Scholar
  34. Henggeler, S. W., Schoenwald, S. K., Borduin, C. M., Rowland, M. D., & Cunningham, P. B. (1998). Multisystemic treatment of antisocial behaviour in children and adolescents. New York: Guildford Press.Google Scholar
  35. Jefferson, J. (1982). The use of lithium in childhood and adolescence: an overview. Journal of Clinical Psychiatry, 43(5), 174–177.PubMedGoogle Scholar
  36. Kafantaris, V., Campbell, M., Padron-Gayol, M., Small, A., Locascio, J., & Rosenberg, C. (1992). Carbamazepine in hospitalized aggressive conduct disordered children: an open pilot study. Psychopharmacology Bulletin, 28(2), 193–199.PubMedGoogle Scholar
  37. Kaplan, S., Busner, J., Kupietz, S., Wasserman, E., & Segal, B. (1990). Effects of methylphenidate on adolescents with aggressive conduct disorder and ADHD: a preliminary report. Journal of American Academy of Child and Adolescent Psychiatry, 29(5), 719–723.CrossRefGoogle Scholar
  38. Kaplan, S., Heiligenstein, J., West, S., Busner, J., Harder, D., Dittman, R., et al. (2004). Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. Journal of Attention Disorders, 8, 45–52.PubMedCrossRefGoogle Scholar
  39. Kemph, J. P., Devane, C. L., Levin, C. M., Jarecke, M., & Millar, R. (1993). Treatment of aggressive children with clonidine, results of an open pilot study. Journal of American Academy of Child and Adolescent Psychiatry, 32, 577–581.CrossRefGoogle Scholar
  40. Klein, R., Abikoff, H., Klass, E., Ganeles, D., Seese, L., & Pollack, S. (1997). Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Archives of General Psychiatry, 54, 1073–1080.PubMedCrossRefGoogle Scholar
  41. Kolko, D., Bukstein, O., & Barron, J. (1999). Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. Journal of American Academy of Child and Adolescent Psychiatry, 38(5), 578–586.CrossRefGoogle Scholar
  42. McNair, D. M., Lorr, M., & Droppleman, L. F. (1971). Profile of mood states manual. San Diego: Educational Industrial Testing Service.Google Scholar
  43. Malone, R. P., Luebbert, R. P., Penea-Areit, M., Biesecker, K., & Delaney, M. A. (1994). The overt aggression scale in a study of lithium in aggressive conduct disorder. Psychopharmacology Bulletin, 30, 215–218.PubMedGoogle Scholar
  44. Malone, R., Delaney, M. A., Luebbert, J., Carter, J., & Campbell, M. (2000). A double blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Archives of General Psychiatry, 57, 649–654.PubMedCrossRefGoogle Scholar
  45. Masi, G., Milone, A., Canepa, G., Millepiedi, S., Mucci, M., & Muratari, F. (2006). Olanzapine treatment in adolescents with severe conduct disorder. European Psychiatry, 21, 51–57.PubMedCrossRefGoogle Scholar
  46. Monroe, R. R. (1970). Episodic behavior disorders: a psychodynamic and neurophysiologic analysis. Cambridge Mass: Harvard University Press.Google Scholar
  47. Moretti, M., Emmrys, C., Grizenko, N., Holland, R., Moore, K., & Shamsie, J. (1997). The treatment of conduct disorder perspectives from across Canada. Canadian Journal of Psychiatry, 42, 637–648.Google Scholar
  48. Mozes, T., Meiri, G., Ben-Amity, G., Sabbagh, M., & Weizman, A. (2005). Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. Journal of Child and Adolescent Psychopharmacology, 15(2), 259–269.PubMedCrossRefGoogle Scholar
  49. Newcorn, J., Spencer, T., Biedeman, J., Milton, D., & Michelson, D. (2005). Atomoxetine treatment in children and adolescents with attention deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of American Academy of Child and Adolescent Psychiatry, 44(3), 240–248.CrossRefGoogle Scholar
  50. Pandina, G., Aman, M., & Findling, R. (2006). Risperidone in the management of disruptive behavior disorder. Journal of Child and Adolescent Psychopharmacology, 16, 379–392.PubMedCrossRefGoogle Scholar
  51. Pandina, G., Bilder, R., Harvey, P., Keefe, R., Aman, M., & Gharabawi, G. (2007). Risperidone and cognitive function in children with disruptive behavior disorder. Biological Psychiatry, 62, 226–234.PubMedCrossRefGoogle Scholar
  52. Pappadopulos, E., Wollston, S., Chait, A., Perks, M., Connor, D., & Jensen, P. (2006). Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. Journal of Canadian Academy of Child and Adolescent Psychiatry, 15(1), 27–39.Google Scholar
  53. Petti, T. A., Fish, B., Shapiro, T., Cohen, I. L., & Campbell, M. (1982). Effects of chlordiazepoxide in disturbed children: a pilot study. Journal of Clinical Psychopharmacology, 2(4), 270–273.PubMedCrossRefGoogle Scholar
  54. Platt, J., Campbell, M., Green, W., & Gregan, D. (1984). Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Archives of General Psychiatry, 41, 657–662.PubMedCrossRefGoogle Scholar
  55. Reyes, M., Buitelaar, J., Toran, P., Augustyns, I., & Erdekens, M. (2006). A randomized double-blind placebo controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. American Journal of Psychiatry, 163(3), 402–410.PubMedCrossRefGoogle Scholar
  56. Reyes, M., Croonenberghs, J., Augustyns, I., & Eerdekens, M. (2006). Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety and tolerability. Journal of Child and Adolescent Psychopharmacology, 16(3), 260–272.PubMedCrossRefGoogle Scholar
  57. Rifkin, A., Karajgi, B., Dicker, R., Peri, E., Boppana, V., Hasan, N., et al. (1997). Lithium treatment of conduct disorders in adolescents. American Journal of Psychiatry, 154(4), 554–555.PubMedGoogle Scholar
  58. Robins, L., Tipp, J., & McEvoy, L. (1991). Antisocial personality. In L. Robins & D. Regier (Eds.), Psychiatric disorders in America (pp. 258–290). New York: New York Free Press.Google Scholar
  59. Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., Carroll, A., & the Risperidone Conduct Study Group. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of American Academy of Child and Adolescent Psychiatry, 41(9), 1026–1036.CrossRefGoogle Scholar
  60. Soderstrom, H., Rastam, M., & Gillberg, C. (2002). A clinical case series of six extremely aggressive youths treated with olanzapine. European Child and Adolescent Psychiatry, 11, 138–141.PubMedCrossRefGoogle Scholar
  61. Steiner, H., Petersen, M., Saxena, K., Ford, S., & Matthews, Z. (2003). Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. Journal of Clinical Psychiatry, 64, 1183–1191.PubMedCrossRefGoogle Scholar
  62. Swanson, J. (1992). School based Assessments and Interviews for ADD. Irvine: KC Publishing.Google Scholar
  63. Van Bellinghen, M., & de Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11(1), 5–13.PubMedCrossRefGoogle Scholar
  64. Weinberger, D. A. (1997). Distress and self-restraint as measures of adjustment across the life span: confirmatory factor analysis in clinical and non-clinical samples. Psychological Assessment, 9, 132–135.CrossRefGoogle Scholar
  65. Yudofsky, S. C., Silver, J. M., Jackson, W., Endicott, J., & Williams, D. (1986). The overt aggression scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry, 143, 35–39.PubMedGoogle Scholar
  66. Zubieta, J., & Alessi, N. (1992). Acute and chronic administration of trazadone in the treatment of disruptive behavior disorders in children. Journal of Clinical Psychopharmacology, 12(6), 346–351.PubMedGoogle Scholar

Copyright information

© Springer New York 2011

Authors and Affiliations

  • Helen L. Smith
    • 1
  • David R. Coghill
    • 1
  1. 1.University of DundeeDundeeScotland

Personalised recommendations